Lakefront Biotherapeutics (LKFT) is trading on Nasdaq as various financial firms issue rating updates, including a buy rating from TD Cowen and price target cuts from Morgan Stanley and RBC.
3 reports, 1 independent
Updated Sep 23
No new developments lately
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Lakefront Biotherapeutics (LKFT) is trading on Nasdaq as various financial firms issue rating updates, including a buy rating from TD Cowen and price target cuts from Morgan Stanley and RBC.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Nasdaq
American fully electronic stock exchange
-
TD Cowen
American investment bank
-
MarketBeat
American personal finance blog
-
Morgan Stanley
U.S. investment bank
Related events
- Financial firms including Royal Bank of Canada, Truist Financial, TD Cowen, and Barclays have announced price target increases for Medpace.
- Royal Bank of Canada and Leerink Partners lowered price targets and ratings for Boston Scientific.
- Rating firms Raymond James Financial and TD Cowen provided reaffirmed buy ratings and price targets for a company listed on Nasdaq.
- MarketBeat reports average rating and target price for SS&C Technologies, while RBC boosts targets and Jefferies reduces its price objective.
- TD Cowen, Morgan Stanley, and other firms issued various ratings and price targets for Circle Internet Group on August 27, 2026.